Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Focus: Bioavailability
Conditions
Focus: Bioavailability
Trial Timeline
Feb 1, 2011 → May 1, 2011
NCT ID
NCT01306123About Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution
Nascobal nasal spray (cyanocobalamin, USP) + Vitamin B12-ratiopharm N, injection solution is a phase 1 stage product being developed by Swedish Orphan Biovitrum for Focus: Bioavailability. The current trial status is completed. This product is registered under clinical trial identifier NCT01306123. Target conditions include Focus: Bioavailability.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01306123 | Phase 1 | Completed |
Competing Products
2 competing products in Focus: Bioavailability
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S303 Red Blood Cells (RBCs) + Conventional, untreated Red Blood Cells (RBCs) | Cerus | Phase 2 | 44 |
| S-303 Red Blood Cells (RBCs) - Test + Conventional, untreated red blood cells (RBCs) - Control | Cerus | Phase 3 | 69 |